Brought to you by 
Series B leads to €18mm for Prosensa BV
06 Jan 2009
Executive Summary
Prosensa BV (uses exon-skipping technology to develop RNAi therapeutics) raised €18mm ($24.3mm) in its Series B financing round co-led by first-time backers GIMV and AGF, which will each contribute a board member. Returning investors Life Science Partners, Abingworth, and MedSciences Capital also participated. Prosensa will use the infusion of capital to move its two lead compounds for Duchenne muscular dystrophy through proof-of-concept trials.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series B leads to €18mm for Prosensa BV
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice